

THERAPEUTICA - PHARMA SERVICES LLC

When you need a partner to grow your business

Blaine Templeman is a proven corporate leader with more than 25 years of experience in managing the operations of multiple clients. Exceptional ability to manage people and matters – select, refine, focus and motivate teams across operations and geography. Consistent track record of collaborating as a leadership team member, building strong organizations, successfully navigating complex challenges and executing organizational changes. Effective mediator, decision-maker and team player. Admitted in NY and registered in CA. While my experience is in running legal departments and operations for biotech, I am focused on the challenge – industry is secondary. My skills translate well. Admitted in NY and registered in CA.

EXPERIENCE

Cartography Biosciences, Inc., 2022-Present

Chief Administrative and Legal Officer and Company Secretary (2023 to present)

Interim COO (2022)

- Currently oversee all aspects of the business other than science.
- Rebuilt IT and Legal departments. Currently rebuilding the finance function.
- Led and conducted all legal work including real estate and contracts. Managed all IP strategy and work.
- Supervising the build out of 58,000 square feet of office and lab space. Struck the deal on the space that saved our company more than \$22M in rent and tenant improvement costs. Reduced costs for furniture, AV/IT and security saving more than \$3M.

Sairopa, B.V., 2021-Present

CLO (part time); completed \$1B plus collaboration transaction at the end of 2022.

Therapeutica, LLP, 2021-Present

Product development and corporate development consulting for biotech projects.

Aduro Biotech, Inc., 2015-2020

Chief Administrative Officer & Chief Legal Officer, Executive Committee Member (2018-2020)

Chief Legal Officer & Secretary, Executive Committee Member (2016-2017)

General Counsel & Secretary, Executive Committee Member (2015-2016)

- Oversaw Legal, Corporate Development, Human Resources, IT, Facilities and Alliance Management teams across US and EU operations; interim lead for quality and regulatory for CMC and clinical
 - Legal
 - Advised Aduro Board of Directors and Leadership Team on key matters related to product development, operations, compensation, policy, disclosures, discipline, corporate strategy and strategic transactions

- Led internal team of four and external relationships with six law firms
- Processed 1200-1500 contracts per year for our bacteria-based and cell-based therapeutics, antibody programs and our STING programs
- Seamlessly integrated legal function into product development
- Developed licensing strategy for our STING resulting in savings of over \$50M in third party payments
- Successfully navigated third party IP concerns thereby avoiding IP litigation
- Created system and processes for setting up CDAs, services agreements and other standard contracts thereby minimizing time to contract
- Created internal system for collaborating and sharing materials for product development projects
- Spearheaded team that sifted through projects and data in search for new IP
- Corporate Development
 - Oversaw department of 2-3 internal FTEs as well as outsourced support for all potential inbound and outbound projects
 - Executed valuable transactions for Aduro: \$750M development deal with Novartis, product R&D collaboration with Eli Lilly, early research deals with UC Berkeley and Johns Hopkins, partnerships for renal, oncology and other antibody assets
 - Led executive leadership team through M&A process for Aduro, which included interaction with over 125 companies
 - Developed strategy and terms for disposition of Aduro's oncology assets
- Alliance Management
 - Managed primary alliances with Novartis, Eli Lilly, and Janssen, as well as 20+ smaller collaborations in support of product development and manufacturing
 - Improved relations with partners
 - Intervened in and proactively resolved potentially controversial issues
 - Identified bottlenecks and costing issues and providing solutions
 - Scripted team and individual interactions with partners
 - Provided partners with first-look opportunities on new technology
 - Simplified alliance management teams and improving turnaround times
- Human Resources
 - Protected company through training and active response team
 - Established a minimum salary for the entire company based on market cost-of-living data
 - Revised salaries and titles in order to simplify corporate structure and devolve operational decision-making throughout the organization
 - Reduced contractor exposure
 - Simplified company policies (creating "guardrails"), thereby increasing ease of compliance
 - Standardized review program while eliminating off-cycle promotions and bonuses
 - Implemented retention program and enhanced company severance program to retain key employees through merger process
 - Led team through 2 carefully planned RIFs while retaining key employees and facilitating successful outplacement of team members for changed programs
- IT

- Supported updates to IT system while reducing team size and contractor dependence
- Supervised updates to laboratory and lab equipment systems
- Tested IT security and remedied weaknesses
- Facilities
 - Oversaw 125,000 square foot facility that included offices, chem labs, CMC manufacturing, hazardous waste, freezer farm and vivarium
 - Updated delivery systems in order to reduce risk of lost supplies and products
 - Improved relationship with landlord through regular meetings, consultations and follow-ups
 - As part of the merger with Chinook and in the midst of shelter in place, subleased the entire Aduro Berkeley building for the remainder of its term for a profit of \$22M

Arnold & Porter LLP, Equity Partner – Technology/IP Transactions, 2014-2015

- Recruited to support IP transactions practice for a retiring partner
- Practice tripled in 11 months prior to going in house with primary client
- Completed key collaboration transactions with Pfizer and Novartis
- Developed team of associates on biotech transactions and clinical contracting

Sheppard Mullin LLP, Equity Partner – Technology/IP Transactions, 2008-2014

Office Managing Partner and Hiring Partner, NYC, 2011-2014

Life Sciences Co-head, 2009-2014

- Key team leader that transformed the NY office of Sheppard Mullin into a profitable office with over 100 attorneys and 50 staff
- Led the Technology and IP Transactions group in creating a profitable clinical contracting practice of national note
- Member of the team that leased and built out the NY office at Rockefeller Plaza

Heller Ehrman LLP, Equity Partner – IP Transactions, 2006-2008

- Expanded practice to include over 40 companies engaged in work across more than 20 countries
- Acted as US counsel to The Serum Institute of India Limited, the world's largest vaccine developer and manufacturer (the manufacturer of the Oxford COVID-19 vaccine)

Mintz Levin LLP, Associate and Equity Partner, 2000-2006

- Originated the firm's branded clinical contracting practice
- Completed all contracting (over 1500 contracts) for the Phase 3 development of Tarceva

Associate Positions at LeBoeuf Lamb LLP and Graham & James LLP, 1994-2000

- Includes family leave to care for parents between engagements

EDUCATION

New York University School of Law, JD 1994

Princeton Seminary, MDiv Candidate 1988-1989

Oral Roberts University, BA (Theology with minors in German and Greek) 1988

HONORS/ACHIEVEMENTS/COMMUNITY

Best Lawyers in America from 2008-2016 for Biotechnology
Outside Counsel to the Gay & Lesbian Alliance Against Defamation (GLAAD)
NYU Law OUTLAW Alumni of the Year (Inaugural Recipient)
Sheppard Mullin Diversity Award Recipient
NYC Bar Association September 11th Pro Bono Legal Services for Business Initiative

NOTABLE DEALS

- Sairopa BV/Exelixis Development Collaboration and Option – anti-SIRPa Antibody
- Lease and Spec Build of 230 South Grand Avenue, South SF
- Sale of Certain Antibody Assets to Van Herk Investments (closed after departure)
- Merger of Aduro Biotech with Chinook Therapeutics
- Sublease of 125,000 square foot Aduro HQ (740 Heinz, Berkeley, CA) to Perfect Day
- Aduro Biotech/Eli Lilly – STING Antagonists – Research Collaboration and License
- Aduro Biotech/Novartis Pharmaceuticals – STING Agonism– Collaboration and License
- Aduro Biotech/Janssen Biotech – LADD in Lung Cancer – Collaboration and License
- Aduro Biotech/Janssen Biotech – LADD in Prostate Cancer – Collaboration and License
- Key STING licenses with MSK, Rutgers, Bonn, Rockefeller, UCB and other third parties
- Found member of the UC Berkeley Immunotherapeutics and Vaccine Research Initiative (funded by Aduro and designed by UCB Tech Transfer and Aduro Legal)
- OPKO/Pfizer – Long acting Human Growth Hormone – License and Development Agreement
- The Serum Institute of India – Deals with Baxter, PATH and WHO

Approach and Values

- Service – Balancing Speed, Quality and Risk
- Mentoring is for Life – I learn your business and priorities; I keep you educated on my work
- Thoughtful Stewardship - Frugal but not Cheap
- Relationships are not Everything – *but Nearly Everything*

Contact

Blaine Templeman – Btempleman@therapeuticabio.com